You are here

P&T® Journal contents for September 2003

Features

Commentary
The media had a field day with the ALLHAT study, but its findings need to be placed into the context of a larger body of evidence.
David B. Nash, MD, MBA, and Janice L. Clarke, RN, BBA
Health Care & Law
A plan from Maine to reduce health care costs for uninsured patients could become a model for the nation.
Robert I. Field, JD, MPH, PhD
Dr. Cunha describes some adverse consequences of antimicrobial therapy.
Burke A. Cunha, MD
Continuing Education Credit
The authors provide an overview of the major antiretroviral medications used to treat AIDS and HIV infection.
Eli Korner, PharmD, MPH, Mary Ellen Bonk, PharmD, Thomas Ratko, PhD, and Karl A. Matuszewski, MS, PharmD

Departments

Editorial
Dr. Matuszewski has several theories as to why we’re listening to the Leapfrog Group’s advice on CPOE.
Karl A. Matuszewski, MS, PharmD
Prescription Washington
Stephen Barlas discusses the DEA’s proposal to cut costs on ordering controlled substances.
Stephen Barlas
Medication Errors
Matthew Grissinger demonstrates why pharmacists need to understand physiology in order to prepare peritoneal dialysis solutions.
Matthew Grissinger, RPh, FASCP
Drug News
P&T presents the latest information about approvals, indication changes, industry updates, and news from the FDA.
Drug Forecast
The authors review enfuvirtide (Fuzeon®), a new agent for the treatment of HIV-1 infection.
Nathaniel Eraikhuemen, PharmD, Evans Branch III, PharmD, Naomi Boston, PharmD, Marlon Honeywell, PharmD, and Kevin Sneed, PharmD
P&T Snapshot
ALLHAT and Diuretics